From the Editor

Sep 01, 2012
Pharmaceutical Executive
Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.
Aug 01, 2012
Pharmaceutical Executive
This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances
Jul 01, 2012
Pharmaceutical Executive
Pharm Exec's 2012 roster of Emerging Leaders—our sixth to date—is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
Jun 01, 2012
Pharmaceutical Executive
As the old Broadway song goes, June is busting out all over—and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.
May 01, 2012
Pharmaceutical Executive
The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.
Apr 01, 2012
Pharmaceutical Executive
Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Mar 01, 2012
Pharmaceutical Executive
Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.
Feb 01, 2012
Pharmaceutical Executive
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
Dec 01, 2011
Pharmaceutical Executive
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.
Nov 01, 2011
Pharmaceutical Executive
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.
native1_300x100
lorem ipsum